Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Preventing Residues in Tissues and Milk- Craig Shultz


Published on

Dr. Shultz presented this material on November 10, 2011 as part of DAIReXNET's webinar entitled "Appropriate Drug Use and Residue Avoidance Practices".

Published in: Education, Technology, Business
  • Be the first to comment

Preventing Residues in Tissues and Milk- Craig Shultz

  1. 1. Ensuring the Wholesomeness of Food Animal Products
  2. 2.  Tissue Residues in Dairy Beef – (circa. 2005) • Surveillance to include non-antibiotic drugs  Flunixin – 2010 Proposed FDA Bulk Milk Sampling Milk Plan - • 26 animal drug residues • Not limited to antibiotics Tissue findings at slaughter drive expanded surveillance in milk
  3. 3.  7.7% of cattle slaughtered in the US are dairy cows – account for 67% of violative residues detected by FSIS in all slaughter cattle.
  4. 4.  Age at slaughter - inflammatory conditions Use – multiple lactations and parturitions Individualvalue – greater incentive to These factors increase the treat complexity of on-farm residue avoidance strategies.
  5. 5.  Complicated in the dairy cow Notsimply a matter of knowing the drug used and its minimum pre-slaughter withhold
  6. 6.  Other equally important factors: • Dosage • Duration of dosage • Route of administration • Use of multiple drugs over time in treating a chronic condition
  7. 7.  Compromised and debilitated animals do not metabolize and eliminate drugs as efficiently as those with normal bodily functions – a VCPR in the culling decision process is critical.
  8. 8.  Accurate treatment record-keeping Veterinarian-Client-Patient Relationship Over-the-counter drugs • Must follow label directions exactly • If you change anything it is extra-label use and you must have a VCPR  Dosage  Duration of dosage  Route of administration VCPR is required for all prescription drugs
  10. 10.  HACCP Final Rule for large plants (1998) Inspected establishment must : • identify hazards in its process • set critical control points with critical limits to control hazards If violative residues are an identified hazard • they must be addressed in HACCP Plan Goal – to reduce hazard to an undetectable level
  11. 11.  Under HACCP, Industry is responsible for • Addressing violations, • Reducing risks • Ensuring the safety of its product Industrymust trace violations, obtain corrective actions and prevent recurrence Industry is required to avoid high risk sources of animals
  12. 12. Feedback Loop ProducerAvoidance HACCP Violations Notification (Days) Slaughter Plant FDA Investigation (Months)
  13. 13.  Onlyhigh risk animals based on ante and post mortem presentation are screened • High quality dairy cows: 5-8% • Lower quality lean dairy cows : up to 15% Tissuesamples from screen-positive animals are submitted to a Federal laboratory for analysis • Identify specific residue in tissue • Amount of residue in tissue
  14. 14.  Violativeresidue levels may be restricted to a tissue (e.g. Kidney) or may involve entire carcass resulting in condemnation Cattle with high violation-risk conditions are screened even if they are condemned on post mortem inspection
  15. 15. Use of Food Animal Drugs and “One Health” Food Safety •Multi-drug resistant food borne pathogens •Public expectation of safe food •Pathogen free raw products •Farm to fork surveillance •Food product liability •Food Product traceability •Food borne illness data Animal Health Public Health •Preventive & disease control •Human Antimicrobial Use antimicrobial use •Immune compromise (HIV, chemo) •Antimicrobial drug availability •Animal drug use and resistance of •Animal traceability human pathogens •Disease data •Disease data Animal Well Being Human Well Being• Perception of animal well being - Companion •Perception of human well beinganimal vs. production animal •Food preferences•Food production practices – different conditions •Food affordability and qualityfor animal vs. human antimicrobial therapy •Antibiotic effectiveness and human•NSAIDS use vs. abuse well-being•Environmental sustainability – carbon •Environmental sustainability – carbonfootprint of intensive animal production footprint of non-intensive animal production